Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00013-1116-83 00013-1116 Doxorubicin Hydrochloride Doxorubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec 23, 1987 Jan 1, 2011 No Longer Used
67457-0495-21 67457-0495 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec 22, 2011 Dec 31, 2017 No Longer Used
00013-1156-79 00013-1156 Doxorubicin Hydrochloride Doxorubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec 23, 1987 Jan 1, 2011 No Longer Used
72064-0125-30 72064-0125 avapritinib Ayvakit 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jun 16, 2021 In Use
00703-5043-01 00703-5043 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sep 1, 1995 Mar 31, 2019 No Longer Used
25021-0213-05 25021-0213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sep 27, 2011 Oct 31, 2016 No Longer Used
58181-4331-04 58181-4331 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Apr 1, 2025 In Use
70121-1237-01 70121-1237 AZACITIDINE AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb 9, 2022 In Use
00009-0082-02 00009-0082 Irinotecan hydrochloride Camptosar 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jun 24, 2024 In Use
50242-0210-90 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Jul 1, 2021 In Use
61703-0408-22 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Feb 26, 2001 Nov 2, 2011 In Use
25021-0255-05 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb 1, 2024 In Use
43975-0307-10 43975-0307 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Mar 20, 2018 Feb 28, 2021 No Longer Used
62856-0718-05 62856-0718 Lenvatinib Lenvima Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral May 17, 2016 In Use
69097-0371-37 69097-0371 Docetaxel Anhydrous Docetaxel Anhydrous 80.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug 24, 2018 Aug 26, 2020 In Use
16714-0909-01 16714-0909 Gemcitabine Hydrochloride Gemcitabine 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Nov 1, 2018 In Use
00069-0251-60 00069-0251 CRIZOTINIB Xalkori 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov 20, 2023 In Use
55150-0376-01 55150-0376 Decitabine Decitabine 50.0 mg/26mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Sep 20, 2021 In Use
59923-0703-05 59923-0703 temozolomide TEMOZOLOMIDE 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan 25, 2019 In Use
00143-9606-01 00143-9606 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jun 8, 2020 In Use
25021-0226-10 25021-0226 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Feb 15, 2023 In Use
43598-0045-63 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov 30, 2022 In Use
42292-0052-05 42292-0052 Erlotinib hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 28, 2019 Feb 28, 2021 No Longer Used
50742-0401-02 50742-0401 Irinotecan Hydrochloride Irinotecan Hydrochloride 40.0 mg/2mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jun 5, 2017 In Use
70771-1708-01 70771-1708 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use

Found 11765 results — Export these results